Developing transcriptomic biomarkers for TAVO412 utilizing next generation sequencing analyses of preclinical tumor models

Developing transcriptomic biomarkers for TAVO412 utilizing next generation sequencing analyses of preclinical tumor models

IntroductionTAVO412, a multi-specific antibody targeting epidermal growth factor receptor (EGFR), mesenchymal epithelial transition factor (c-Met), and vascular endothelial growth factor A (VEGF-A), is undergoing clinical development for the treatment of solid tumors. TAVO412 has multiple mechanism...

Full description

Saved in:
Bibliographic Details
Main Authors: Ying Jin, Peng Chen, Huajun Zhou, Guangmao Mu, Simin Wu, Zhengxia Zha, Bin Ma, Chao Han, Mark L. Chiu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Immunology
Subjects:
EGFR cancer cells +
cmet
VEGF - vascular endothelial growth factor
antibodies
PDX (patient derived xenograft)
CDx
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1505868/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1505868/full

Similar Items